Marketwire -- London, UK; Brentwood, TN, US: 14 August 2008 - Protherics PLC (“Protherics” or the “Company”), the international biopharmaceutical company focused on critical care and cancer, announces that on 13 August 2008, in accordance with the Transparency Obligations Directive, a notification of interest in the ordinary share capital of the Company was received from AXA Investment Managers UK Limited on behalf of AXA S.A. and its Group Companies (“AXA”). The notification follows an increase in its Indirect Voting Rights. Details of the interest notified are as follows:
